The comparative effectiveness of COVID-19 monoclonal antibodies: A learning health system randomized clinical trial

BACKGROUND: Monoclonal antibodies (mAb) that neutralize SARS-CoV-2 decrease hospitalization and death compared to placebo in patients with mild to moderate COVID-19; however, comparative effectiveness is unknown. We report the comparative effectiveness of bamlanivimab, bamlanivimab-etesevimab, and c...

Descripción completa

Detalles Bibliográficos
Autores principales: McCreary, Erin K., Bariola, J. Ryan, Minnier, Tami E., Wadas, Richard J., Shovel, Judith A., Albin, Debbie, Marroquin, Oscar C., Kip, Kevin E., Collins, Kevin, Schmidhofer, Mark, Wisniewski, Mary Kay, Nace, David A., Sullivan, Colleen, Axe, Meredith, Meyers, Russell, Weissman, Alexandra, Garrard, William, Peck-Palmer, Octavia M., Wells, Alan, Bart, Robert D., Yang, Anne, Berry, Lindsay R., Berry, Scott, Crawford, Amy M., McGlothlin, Anna, Khadem, Tina, Linstrum, Kelsey, Montgomery, Stephanie K., Ricketts, Daniel, Kennedy, Jason N., Pidro, Caroline J., Haidar, Ghady, Snyder, Graham M., McVerry, Bryan J., Yealy, Donald M., Angus, Derek C., Nakayama, Anna, Zapf, Rachel L., Kip, Paula L., Seymour, Christopher W., Huang, David T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9187853/
https://www.ncbi.nlm.nih.gov/pubmed/35697146
http://dx.doi.org/10.1016/j.cct.2022.106822

Ejemplares similares

Ejemplares similares